Synlogic Inc (MIN.MU)
- Simply Wall St.
We Think Synlogic (NASDAQ:SYBX) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Zacks
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company recently announced the decision to discontinue Synpheny-3, its pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria (PKU) and evaluate strategic options for the Company. Fourth Quarter 202
